ArticleScientific reports2017
Fecal Bacterial Communities in treated HIV infected individuals on two antiretroviral regimens.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 3 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- The Impact of Human Immunodeficiency Virus Infection on Gut Microbiota α-Diversity: An Individual-level Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Pooled it
- Gut Microbiome Changes Associated With HIV Infection and Sexual Orientation.Frontiers in cellular and infection microbiology · 2020Pooled it
- Gut microbiota phenotypes of obesity.NPJ biofilms and microbiomesPooled it
- Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- Limited impact of HIV infection and immune status on the gut mycobiota.BMC microbiology · 2026Article
- Integrase inhibitor-based antiretroviral therapy drives gut microbiota remodeling and immune recovery in HIV infection.Frontiers in medicine · 2026Article
- Linking the relationship between drug-induced osteoporosis and the gut microbiota.Frontiers in endocrinology · 2026Review
- Differential effects of switching to integrase strand transfer inhibitors on the gut microbiota and markers of HIV disease progression.BMC microbiology · 2025Article
- Patterns of immune recovery in people living with HIV who initiated antiretroviral therapy as late presenters.BMC infectious diseases · 2025Article
- Composite quantile regression approach to batch effect correction in microbiome data.Frontiers in microbiology · 2025Article
- HIV and the gut: implications for HIV persistence, immune dysfunction and cure strategies.Frontiers in immunology · 2025Review
- Research trends of next generation probiotics.Food science and biotechnology · 2024Review
- Review
- A Two-Faced Gut Microbiome: Butyrogenic and Proinflammatory Bacteria Predominate in the Intestinal Milieu of People Living with HIV from Western Mexico.International journal of molecular sciences · 2024Article
- Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe.Microbiome · 2024Article
- The Gut and the Translocated Microbiomes in HIV Infection: Current Concepts and Future Avenues.Pathogens & immunity · 2024Review
- Mechanisms of HIV-immunologic non-responses and research trends based on gut microbiota.Frontiers in immunology · 2024Review
- Impaired gut microbiota-mediated short-chain fatty acid production precedes morbidity and mortality in people with HIV.Cell reports · 2023Article
- Antiretroviral treatment is less effective at reducing gut microbiome-associated inflammation and T cell activation in people living with HIV in rural versus urban Zimbabwe.Research square · 2023Article
- Therapeutically targeting the consequences of HIV-1-associated gastrointestinal dysbiosis: Implications for neurocognitive and affective alterations.Pharmacology, biochemistry, and behavior · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Intestinal microbiome changes that occur in HIV positive individuals on different antiretroviral therapy (ART) regimens are important to understand, as they are potentially linked with chronic inflammation and microbiome-linked comorbidities that occur at increased incidence in this population. We conducted a cross-sectional study comparing the fecal microbiomes of HIV-uninfected (HIV SN) to HIV-infected individuals on long-term ART (HIV+ LTART) from Mexico using 16S ribosomal RNA (16sRNA) targeted sequencing. These individuals were on two ART regimens based on either Non-Nucleoside Reverse Transcriptase Inhibitors (EFV) or ritonavir-boosted Protease Inhibitors (PI) with the same backbone of Nucleoside Reverse Transcriptase Inhibitors. Microbiome diversity was reduced in treated HIV infection compared to HIV SN (p < 0.05). Several operational taxonomic units (OTUs) related to the Ruminococcaceae family including Faecalibacterium prausnitzii were depleted in EFV and PI compared to HIV SN and negatively correlated with intestinal gut dysfunction as measured by the intestinal fatty binding protein (p < 0.05). This is the first report to address the fecal bacterial communities in HIV-infected individuals on two ARV regimens from Mexico.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.